Re: Regulus Stock Sales
I can't say I agree with Alnylam selling down its stake in Regulus. Still very early for miRNAs, but some disruptive potential there, and it's not like the balance sheet is hurting.
miRNAs have kind of faded into the background amidst buzz over new platforms like gene editing, but that may just mean that they're turning the corner into actual clinical translation. The biology seems much trickier than the monogenic diseases that Alnylam is focused on, which is why I'm hesitant to directly invest in them, but it's a nice bonus to own a piece of it through ALNY.